Bionomics BNC210 Expansion into Social Anxiety Disorder
Bionomics BNC210 Expansion into Social Anxiety Disorder News provided by Share this article Share this article Rapid oral absorption of BNC210 novel tablet formulation ideally suited for acute treatment of anxiety in patients with Social Anxiety Disorder BNC210 Phase 2b PTSD trial on target for start in mid-2021 with U.S. CRO Premier Research selected and clinical site identification underway Pipeline expansion puts Company on path for two Phase 2 programs underway in 2021 ADELAIDE, Australia, May 10, 2021 /PRNewswire/ -- Bionomics Limited (OTCQB:BNOEF) ( Bionomics or Company), a global, c...
Source: prnewswire.com